Expanded Access to RXDX-105 for Cancers With RET Alterations
1 other identifier
expanded_access
N/A
1 country
1
Brief Summary
Expanded access to RXDX-105 will be given to patients with cancers harboring RET alterations who have not received TKIs that target RET alterations, who do not qualify for participation in, or who are otherwise unable to access, an ongoing clinical trial for RXDX-105.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 10, 2017
CompletedFirst Posted
Study publicly available on registry
February 14, 2017
CompletedApril 26, 2019
April 1, 2019
February 10, 2017
April 24, 2019
Conditions
Interventions
Oral Capsules
Eligibility Criteria
You may qualify if:
- Diagnosis of advanced cancer with RET alterations
- Unable to participate in an ongoing RXDX-105 clinical trial
- Willing and able to provide written, signed informed consent
- Medically suitable for treatment with RXDX-105
You may not qualify if:
- Prior treatment with a TKI that has activity against RET alterations
- Currently enrolled in an ongoing clinical study with any other investigational agent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Www.Ignyta.Com
San Diego, California, 92121, United States
MeSH Terms
Interventions
Study Design
- Study Type
- expanded access
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 10, 2017
First Posted
February 14, 2017
Last Updated
April 26, 2019
Record last verified: 2019-04